Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile

Marika A. Artz*, Johannes M.M. Boots, Gerry Ligtenberg, Joke I. Roodnat, Maarten H.L. Christiaans, Pieter F. Vos, Philip Moons, George Borm, Luuk B. Hilbrands

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

139 Citations (Scopus)

Abstract

Long-term use of cyclosporine after renal transplantation results in nephrotoxicity and an increased cardiovascular risk profile. Tacrolimus may be more favorable in this respect. In this randomized controlled study in 124 renal-transplant patients, the effects of conversion from cyclosporine to tacrolimus on renal function, cardiovascular risk factors, and perceived side-effects were investigated after a follow-up of 2 years. After conversion from cyclosporine to tacrolimus renal function remained stable, whereas continuation of cyclosporine was accompanied by a rise in serum creatinine from 142 ± 48 μmol/L to 157 ± 62 μmol/L (p < 0.05 comparing both groups). Conversion to tacrolimus resulted in a sustained reduction in systolic and diastolic blood pressure, and a sustained improvement in the serum lipid profile, leading to a reduction in the Framingham risk score from 5.7 ± 4.3 to 4.8 ± 5.3 (p < 0.05). Finally, conversion to tacrolimus resulted in decreased scores for occurrence of and distress due to side-effects. In conclusion, conversion from cyclosporine to tacrolimus in stable renal-transplant patients is beneficial with respect to renal function, cardiovascular risk profile, and side-effects. Therefore, for most renal transplant patients tacrorimus will be the drug of choice when long-term treatment with a calcineurin inhibitor is indicated.

Original languageEnglish
Pages (from-to)937-945
Number of pages9
JournalAmerican Journal of Transplantation
Volume4
Issue number6
DOIs
Publication statusPublished - Jun 2004

Research programs

  • EMC MM-04-39-05

Fingerprint

Dive into the research topics of 'Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile'. Together they form a unique fingerprint.

Cite this